The second line cabazitaxel [1], the immunotherapy sipuluecel-T [2], the androgen synthesis inhibitor abiraterone acetate [3] the AR antagonist enzalutamide [4] and the alpha particle emitter radium-223 [5] have all received recent FDA approval for the treatment of advanced PCa. The gene discussed is AR; the disease is posterior cortical atrophy.